Alcibiades Rodriguez, MD
Clinical Neurophysiology · New York, NYNPI 1831151281
Payments from drug & device makers
Across 896 payments — averaging $798.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$321K
- Axsome Therapeutics, Inc.$144K
- Lilly USA, LLC$100K
- Harmony Biosciences LLC$82K
- Avadel CNS Pharmaceuticals, LLC$59K
- Eisai Inc.$5K
- plus $5K from 14 others
What the payments were for
- Consulting fees$123,30417%
- Speaking & faculty fees$471,33566%
- Travel & lodging$92,44513%
- Food & beverage$26,3684%
- Education$6790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 329 | $321,090 |
| Axsome Therapeutics, Inc. | 110 | $143,845 |
| Lilly USA, LLC | 136 | $99,857 |
| Harmony Biosciences LLC | 171 | $82,146 |
| Avadel CNS Pharmaceuticals, LLC | 59 | $59,086 |
| Eisai Inc. | 2 | $4,918 |
| Neurelis, Inc. | 42 | $1,366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $1,316 |
| Livanova USA, Inc. | 1 | $800 |
| UCB, Inc. | 8 | $355 |
| Amgen | 8 | $238 |
| Inspire Medical Systems, Inc. | 6 | $176 |
| SK Life Science, Inc. | 5 | $141 |
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| ZOLL Respicardia, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $21 |
| Resmed Corp | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$715,631 in reported general payments places this provider in the 95th percentile of 35 clinical neurophysiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 31 | $619,141 |
| WakixPitolisant Hcl | 20 | $311,499 |
| LumryzSodium Oxybate | 12 | $239,796 |
| VimpatLacosamide | 13 | $65,927 |
| BriviactBrivaracetam | 13 | $39,500 |
| SunosiSolriamfetol Hcl | 30 | $31,567 |
| LunestaEszopiclone | 24 | $20,665 |
| Adderall XrDextroamphetamine/Amphetamine | 14 | $7,357 |
| Zaleplon | 102 | $2,205 |
| Doxepin Hcl | 38 | $1,284 |
| Quetiapine Fumarate | 27 | $812 |
| Zolpidem Tartrate | 94 | $583 |
| Gabapentin | 42 | $501 |
| Eszopiclone | 37 | $428 |
| Trazodone Hcl | 27 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $82,146 | $311,49920 claims |
| Avadel CNS Pharmaceuticals, LLCLumryz | $59,086 | $239,79612 claims |
| UCB, Inc.Vimpat, Briviact | $355 | $105,42826 claims |
| Axsome Therapeutics, Inc.Sunosi | $143,845 | $31,56730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 clinical neurophysiology providers in New York.
Other clinical neurophysiology in New York
- Jessica Robinson-PappNew York$74K
- Madeline FieldsNew York$5K
- Agnieszka KokoszkaNew York$5K
- Cristina DraftaNew York$2K
- Andrei CarascaNew York$2K
- Kiril KiprovskiNew York$488
- James YoungNew York$256
- Jonathan VictorNew York$124
- Samuel RapoportNew York$16
- Farhad Kadkhodaei ElyaderaniBronx$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.